RU2019112919A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2019112919A3 RU2019112919A3 RU2019112919A RU2019112919A RU2019112919A3 RU 2019112919 A3 RU2019112919 A3 RU 2019112919A3 RU 2019112919 A RU2019112919 A RU 2019112919A RU 2019112919 A RU2019112919 A RU 2019112919A RU 2019112919 A3 RU2019112919 A3 RU 2019112919A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Reverberation, Karaoke And Other Acoustics (AREA)
- Bipolar Transistors (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16191454.4 | 2016-09-29 | ||
EP16191454 | 2016-09-29 | ||
EP17155846.3 | 2017-02-13 | ||
EP17155846 | 2017-02-13 | ||
PCT/EP2017/074594 WO2018060312A1 (en) | 2016-09-29 | 2017-09-28 | Pth compounds with low peak-to-trough ratios |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2022102002A Division RU2022102002A (ru) | 2016-09-29 | 2017-09-28 | Птг-соединения с низкими соотношениями пика и минимума |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2019112919A RU2019112919A (ru) | 2020-10-30 |
RU2019112919A3 true RU2019112919A3 (ru) | 2021-01-19 |
RU2766959C2 RU2766959C2 (ru) | 2022-03-16 |
Family
ID=60051489
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2019112919A RU2766959C2 (ru) | 2016-09-29 | 2017-09-28 | Птг-соединения с низкими соотношениями пика и минимума |
Country Status (25)
Country | Link |
---|---|
US (4) | US11759504B2 (ru) |
EP (2) | EP4218795A3 (ru) |
JP (2) | JP7085535B2 (ru) |
KR (2) | KR102611820B1 (ru) |
CN (2) | CN117257922A (ru) |
AU (1) | AU2017336251B2 (ru) |
BR (1) | BR112019005793A2 (ru) |
CA (1) | CA3037447A1 (ru) |
DK (1) | DK3518961T3 (ru) |
ES (1) | ES2943720T3 (ru) |
FI (1) | FI3518961T3 (ru) |
HR (1) | HRP20230383T1 (ru) |
HU (1) | HUE062009T2 (ru) |
IL (1) | IL265601A (ru) |
LT (1) | LT3518961T (ru) |
MA (1) | MA46345A (ru) |
MX (1) | MX2019003182A (ru) |
NZ (1) | NZ751745A (ru) |
PL (1) | PL3518961T3 (ru) |
RS (1) | RS64177B1 (ru) |
RU (1) | RU2766959C2 (ru) |
SG (1) | SG11201901558VA (ru) |
SI (1) | SI3518961T1 (ru) |
WO (1) | WO2018060312A1 (ru) |
ZA (1) | ZA201901813B (ru) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2964463C (en) | 2014-10-22 | 2024-02-13 | Extend Biosciences, Inc. | Therapeutic vitamin d conjugates |
US9616109B2 (en) | 2014-10-22 | 2017-04-11 | Extend Biosciences, Inc. | Insulin vitamin D conjugates |
KR20230015517A (ko) | 2016-03-01 | 2023-01-31 | 아센디스 파마 본 디지즈 에이/에스 | Pth 프로드럭 |
SI3518960T1 (sl) | 2016-09-29 | 2023-11-30 | Ascendis Pharma Bone Diseases A/S, | Odmerni režim za PTH spojino z nadzorovanim sproščanjem |
CA3037447A1 (en) | 2016-09-29 | 2018-04-05 | Ascendis Pharma Bone Diseases A/S | Pth compounds with low peak-to-trough ratios |
JP2021516222A (ja) * | 2018-03-16 | 2021-07-01 | ザ ジェネラル ホスピタル コーポレイション | 副甲状腺ホルモンポリペプチドコンジュゲートおよびその使用方法 |
AU2020221491A1 (en) | 2019-02-11 | 2021-08-05 | Ascendis Pharma Bone Diseases A/S | Liquid pharmaceutical formulations of PTH conjugates |
CA3161101A1 (en) | 2020-01-13 | 2021-07-22 | Kennett Sprogoe | Hypoparathyroidism treatment |
KR20230079255A (ko) | 2020-09-28 | 2023-06-05 | 아센디스 파마 본 디지즈 에이/에스 | 부갑상선 기능 저하증 환자의 신체적 및 정신적 웰빙 개선 |
AU2022350937A1 (en) | 2021-09-22 | 2024-03-21 | Ascendis Pharma Bone Diseases A/S | Long-acting pth compound treatments |
WO2024094673A1 (en) * | 2022-11-02 | 2024-05-10 | Ascendis Pharma Bone Diseases A/S | Pth treatment regimen comprising two pth compounds |
Family Cites Families (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5744444A (en) | 1989-10-27 | 1998-04-28 | Haemopep Pharma Gmbh | HPTH-fragment-(1-37), the preparation thereof, medicaments containing same and the use thereof |
US5567439A (en) | 1994-06-14 | 1996-10-22 | Fuisz Technologies Ltd. | Delivery of controlled-release systems(s) |
ZA9811127B (en) | 1997-12-09 | 2000-07-11 | Lilly Co Eli | Stabilized teriparatide solutions. |
US6624142B2 (en) | 1997-12-30 | 2003-09-23 | Enzon, Inc. | Trimethyl lock based tetrapartate prodrugs |
US20050124537A1 (en) | 2000-04-27 | 2005-06-09 | Amgen Inc. | Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein |
JPWO2003064462A1 (ja) | 2002-02-01 | 2005-05-26 | 中外製薬株式会社 | Peg結合pth又はpeg結合pth誘導体 |
US6559293B1 (en) | 2002-02-15 | 2003-05-06 | Transform Pharmaceuticals, Inc. | Topiramate sodium trihydrate |
US7122189B2 (en) | 2002-08-13 | 2006-10-17 | Enzon, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
US7332164B2 (en) | 2003-03-21 | 2008-02-19 | Enzon Pharmaceuticals, Inc. | Heterobifunctional polymeric bioconjugates |
DK1620118T3 (da) | 2003-04-08 | 2014-09-29 | Yeda Res & Dev | Reversible pegylerede lægemidler |
US7690003B2 (en) | 2003-08-29 | 2010-03-30 | Fuller Jeffrey C | System and method for increasing data throughput using thread scheduling |
EP1670515A2 (en) | 2003-09-19 | 2006-06-21 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
EP2087910B1 (en) | 2004-03-23 | 2022-05-04 | Ascendis Pharma GmbH | Polymeric prodrugs |
RU2006143544A (ru) | 2004-05-10 | 2008-06-20 | Нэстек Фармасьютикал Кампани Инк. (Us) | Композиции и способ для облегченной чресслизистой доставки паратиреоидного гормона |
US7968085B2 (en) | 2004-07-05 | 2011-06-28 | Ascendis Pharma A/S | Hydrogel formulations |
CN1597697A (zh) | 2004-07-19 | 2005-03-23 | 中国药科大学 | 一种人的甲状旁腺素1-34肽相关肽-Pro-Pro-[Arg11]]hPTH(1-34)-Pro-Pro |
US20060069021A1 (en) * | 2004-08-13 | 2006-03-30 | Nastech Pharmaceutical Company Inc. | Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs |
WO2006059237A1 (en) | 2004-08-30 | 2006-06-08 | Lunamed, Inc. | 4-phenylbutyric acid controlled-release formulations for therapeutic use |
GB2427360A (en) | 2005-06-22 | 2006-12-27 | Complex Biosystems Gmbh | Aliphatic prodrug linker |
CN1298386C (zh) | 2005-08-31 | 2007-02-07 | 上海交通大学 | 甲状旁腺激素缓释微球的制备方法 |
US8450269B2 (en) | 2006-02-03 | 2013-05-28 | Prolor Biotech Ltd. | Long-acting growth hormone and methods of producing same |
CN101466393A (zh) | 2006-03-15 | 2009-06-24 | 阿尔扎公司 | 用于经皮递送甲状旁腺激素药剂以治疗骨质减少的方法 |
JP2010503707A (ja) | 2006-09-15 | 2010-02-04 | エンゾン ファーマスーティカルズ インコーポレイテッド | オリゴヌクレオチドの送達を目的としたヒンダードエステル系生体分解性リンカー |
CN101522709B (zh) | 2006-10-13 | 2013-03-20 | 伊莱利利公司 | 作为pth受体调节剂的聚乙二醇化的pth及其用途 |
US8101729B2 (en) | 2007-03-19 | 2012-01-24 | Henry Joseph Niemczyk | Pegylated amino acid derivatives and the process to synthesize the same |
JP5520811B2 (ja) | 2007-04-09 | 2014-06-11 | ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー | コラーゲン結合領域と副甲状腺ホルモンとの融合タンパク |
CN101063125A (zh) | 2007-04-17 | 2007-10-31 | 江南大学 | 人甲状旁腺激素与人血清白蛋白的融合蛋白的制备方法及产品 |
SI2173890T1 (sl) | 2007-06-21 | 2011-06-30 | Univ Muenchen Tech | Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost |
WO2009009712A1 (en) | 2007-07-11 | 2009-01-15 | Enzon Pharmaceuticals, Inc. | Polymeric drug delivery system containing a multi-substituted aromatic moiety |
EP2052736A1 (en) | 2007-10-26 | 2009-04-29 | Nycomed Danmark ApS | Parathyroid hormone formulations und uses thereof |
CA2712224C (en) | 2008-02-01 | 2016-03-08 | Ascendis Pharma As | Prodrug comprising a drug linker conjugate |
MX344559B (es) | 2008-04-29 | 2016-12-20 | Ascendis Pharma As | Compuestos de hormona de crecimiento humana recombinante unidos al peg. |
WO2009143412A2 (en) | 2008-05-23 | 2009-11-26 | Enzon Pharmaceuticals, Inc. | Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides |
WO2009156481A1 (en) | 2008-06-25 | 2009-12-30 | Ascendis Pharma As | Pegylated bnp |
US20110195900A1 (en) | 2008-08-19 | 2011-08-11 | Ferring B.V. | Peptidic pth receptor agonists |
BR122021021381B1 (pt) | 2009-02-03 | 2023-05-16 | Amunix Pharmaceuticals, Inc | Método de aprimoramento de uma propriedade de uma proteína biologicamente ativa |
CA2769340C (en) | 2009-07-31 | 2018-09-11 | Harald Rau | Prodrugs comprising an insulin linker conjugate |
US20120191039A1 (en) * | 2009-07-31 | 2012-07-26 | Ascendis Pharma A/S | Carrier linked pramipexole prodrugs |
WO2011012723A1 (en) | 2009-07-31 | 2011-02-03 | Ascendis Pharma As | Injectable sustained release compositions comprising a pramipexole prodrug |
EP2459227B1 (en) | 2009-07-31 | 2021-03-17 | Ascendis Pharma A/S | Prodrugs containing an aromatic amine connected by an amide bond to a carrier |
AU2010277560B2 (en) * | 2009-07-31 | 2014-12-11 | Sanofi-Aventis Deutschland Gmbh | Long acting insulin composition |
ES2833035T3 (es) | 2009-07-31 | 2021-06-14 | Ascendis Pharma As | Hidrogeles biodegradables insolubles en agua a base de polietilenglicol |
ITMI20091512A1 (it) | 2009-08-28 | 2011-02-28 | Al Ma C Packaging S R L | Procedimento per il confezionamento di gruppi di contenitori per prodotti liquidi alimentari, in particolare bottiglie di acqua e/o bevande, e fardello ottenibile per mezzo di tale procedimento |
US20130053405A1 (en) * | 2009-10-06 | 2013-02-28 | Ulrich Hersel | Carrier linked paliperidone prodrugs |
DK2512450T3 (en) | 2009-12-15 | 2018-04-23 | Ascendis Pharma Endocrinology Div A/S | Dry growth hormone composition transiently bound to a polymer carrier |
WO2011082368A2 (en) | 2009-12-31 | 2011-07-07 | Enzon Pharmaceuticals, Inc | Polymeric conjugates of aromatic amine containing compounds including releasable urea linker |
EP2525829A1 (en) | 2010-01-22 | 2012-11-28 | Ascendis Pharma A/S | Dipeptide-based prodrug linkers for aromatic amine-containing drugs |
EP2525830B1 (en) | 2010-01-22 | 2016-05-11 | Ascendis Pharma A/S | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs |
EP2525831B1 (en) * | 2010-01-22 | 2019-05-15 | Ascendis Pharma A/S | Carrier-linked carbamate prodrug linkers |
US20110229580A1 (en) | 2010-03-22 | 2011-09-22 | Indian Institute of Technology Bombay, School of Biosciences and Bioengineering | Compositions and methods for nano-in-micro particles |
WO2011123813A2 (en) | 2010-04-02 | 2011-10-06 | Amunix Operating Inc. | Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same |
EP2566334B1 (en) | 2010-05-05 | 2018-04-18 | Prolynx, LLC | Controlled drug release from solid supports |
WO2011140393A1 (en) | 2010-05-05 | 2011-11-10 | Prolynx Llc | Controlled release from macromolecular conjugates |
WO2011143406A2 (en) | 2010-05-13 | 2011-11-17 | The General Hospital Corporation | Parathyroid hormone analogs and uses thereof |
CN105477641B (zh) | 2010-05-21 | 2021-03-23 | Xl-蛋白有限责任公司 | 生物合成的脯氨酸/丙氨酸无规卷曲多肽及其用途 |
US8865220B2 (en) * | 2010-06-14 | 2014-10-21 | Kaohsiung Medical University | Method for controlled release of parathyroid hormone from encapsulated poly(lactic-glycolic)acid microspheres |
US8989456B2 (en) | 2010-06-30 | 2015-03-24 | Nec Solution Innovators, Ltd. | Attribute determining method, attribute determining apparatus, program, recording medium, and attribute determining system |
US20120040320A1 (en) | 2010-08-13 | 2012-02-16 | Nadeau Daniel A | Injection Simulation Device and Methods Thereof |
EP2438930A1 (en) | 2010-09-17 | 2012-04-11 | Sanofi-Aventis Deutschland GmbH | Prodrugs comprising an exendin linker conjugate |
CN103874480A (zh) * | 2011-08-12 | 2014-06-18 | 阿森迪斯药物股份有限公司 | 前列环素的缓释组合物 |
EP2741781A1 (en) | 2011-08-12 | 2014-06-18 | Ascendis Pharma A/S | Carrier-linked treprostinil prodrugs |
AU2012296951B2 (en) * | 2011-08-12 | 2016-09-15 | Ascendis Pharma A/S | Protein carrier-linked prodrugs |
AU2012296950B2 (en) | 2011-08-12 | 2016-09-22 | Ascendis Pharma A/S | Polymeric hyperbranched carrier-linked prodrugs |
US20140249093A1 (en) * | 2011-08-12 | 2014-09-04 | Ascendis Pharma A/S | Carrier-Linked Prodrugs Having Reversible Carboxylic Ester Linkages |
WO2013036857A1 (en) | 2011-09-07 | 2013-03-14 | Prolynx Llc | Sulfone linkers |
CN104010626A (zh) | 2011-10-12 | 2014-08-27 | 阿森迪斯药物眼科部股份有限公司 | 眼病症的预防和治疗 |
US8883862B2 (en) | 2012-01-12 | 2014-11-11 | Kaohsiung Medical University | Method for controlled release of parathyroid hormone from cross-linked hyaluronic acid hydrogel |
EP2841109A1 (en) | 2012-04-25 | 2015-03-04 | Ascendis Pharma A/S | Prodrugs of hydroxyl-comprising drugs |
US9457096B2 (en) | 2012-07-06 | 2016-10-04 | Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Concet) | Protozoan variant-specific surface proteins (VSP) as carriers for oral drug delivery |
US9718868B2 (en) | 2012-08-28 | 2017-08-01 | The Governors Of The University Of Alberta | Parathyroid hormone, insulin, and related peptides conjugated to bone targeting moieties and methods and making and using thereof |
EP2906246B1 (en) * | 2012-10-11 | 2023-07-26 | Ascendis Pharma Ophthalmology Division A/S | Vegf neutralizing prodrugs comprising ranibizumab for the treatment of ocular conditions characterized by ocular neovascularization |
AU2013328774B2 (en) * | 2012-10-11 | 2017-11-30 | Ascendis Pharma A/S | Diagnosis, prevention and treatment of diseases of the joint |
CA2883833C (en) * | 2012-10-11 | 2020-10-27 | Ascendis Pharma A/S | Hydrogel prodrugs |
US20150250882A1 (en) | 2012-10-17 | 2015-09-10 | Novo Nordisk Health Care Ag | Fatty Acid Acylated Amino Acids for Growth Hormone Delivery |
JP6290243B2 (ja) * | 2012-12-07 | 2018-03-07 | アセンディス ファーマ エー/エス | 担体連結プロスタノイドプロドラッグ |
GB201303771D0 (en) | 2013-03-04 | 2013-04-17 | Midatech Ltd | Nanoparticles peptide compositions |
WO2014173759A1 (en) | 2013-04-22 | 2014-10-30 | Ascendis Pharma A/S | Hydrogel-linked prodrugs releasing modified drugs |
US20150065423A1 (en) | 2013-08-30 | 2015-03-05 | Perosphere, Inc. | Rapid acting injectable formulations |
US10040850B2 (en) | 2013-10-08 | 2018-08-07 | Ascendis Pharma A/S | Protecting group comprising a purification tag |
EP2868326A1 (en) | 2013-11-04 | 2015-05-06 | Université Pierre et Marie Curie (Paris 6) | Peptide inhibitors of TEAD/YAP-TAZ interaction |
US11633487B2 (en) | 2014-08-06 | 2023-04-25 | Ascendis Pharma A/S | Prodrugs comprising an aminoalkyl glycine linker |
CA2964463C (en) * | 2014-10-22 | 2024-02-13 | Extend Biosciences, Inc. | Therapeutic vitamin d conjugates |
MX2017008915A (es) | 2015-01-09 | 2018-04-26 | Ascendis Pharma Growth Disorders As | Profarmacos de peptido natriuretico tipo c (cnp). |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
KR20230015517A (ko) | 2016-03-01 | 2023-01-31 | 아센디스 파마 본 디지즈 에이/에스 | Pth 프로드럭 |
SI3518960T1 (sl) | 2016-09-29 | 2023-11-30 | Ascendis Pharma Bone Diseases A/S, | Odmerni režim za PTH spojino z nadzorovanim sproščanjem |
PT3518930T (pt) | 2016-09-29 | 2023-04-28 | Ascendis Pharma Growth Disorders As | Terapia de combinação com agonistas de cnp de libertação controlada |
AU2017336250C1 (en) | 2016-09-29 | 2023-08-03 | Ascendis Pharma Bone Diseases A/S | Incremental dose finding in controlled-release PTH compounds |
CA3037447A1 (en) | 2016-09-29 | 2018-04-05 | Ascendis Pharma Bone Diseases A/S | Pth compounds with low peak-to-trough ratios |
AR110299A1 (es) | 2016-12-02 | 2019-03-13 | Sanofi Sa | Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico |
WO2019219896A1 (en) | 2018-05-18 | 2019-11-21 | Ascendis Pharma Bone Diseases A/S | Starting dose of pth conjugates |
AU2020221491A1 (en) | 2019-02-11 | 2021-08-05 | Ascendis Pharma Bone Diseases A/S | Liquid pharmaceutical formulations of PTH conjugates |
CA3161101A1 (en) | 2020-01-13 | 2021-07-22 | Kennett Sprogoe | Hypoparathyroidism treatment |
-
2017
- 2017-09-28 CA CA3037447A patent/CA3037447A1/en active Pending
- 2017-09-28 MA MA046345A patent/MA46345A/fr unknown
- 2017-09-28 EP EP23157504.4A patent/EP4218795A3/en active Pending
- 2017-09-28 HR HRP20230383TT patent/HRP20230383T1/hr unknown
- 2017-09-28 RU RU2019112919A patent/RU2766959C2/ru active
- 2017-09-28 WO PCT/EP2017/074594 patent/WO2018060312A1/en unknown
- 2017-09-28 NZ NZ751745A patent/NZ751745A/en unknown
- 2017-09-28 SI SI201731350T patent/SI3518961T1/sl unknown
- 2017-09-28 HU HUE17781427A patent/HUE062009T2/hu unknown
- 2017-09-28 EP EP17781427.4A patent/EP3518961B1/en active Active
- 2017-09-28 PL PL17781427.4T patent/PL3518961T3/pl unknown
- 2017-09-28 MX MX2019003182A patent/MX2019003182A/es unknown
- 2017-09-28 RS RS20230344A patent/RS64177B1/sr unknown
- 2017-09-28 FI FIEP17781427.4T patent/FI3518961T3/fi active
- 2017-09-28 CN CN202311052760.2A patent/CN117257922A/zh active Pending
- 2017-09-28 US US16/337,955 patent/US11759504B2/en active Active
- 2017-09-28 CN CN201780060139.7A patent/CN109789188B/zh active Active
- 2017-09-28 JP JP2019516692A patent/JP7085535B2/ja active Active
- 2017-09-28 KR KR1020197012458A patent/KR102611820B1/ko active IP Right Grant
- 2017-09-28 DK DK17781427.4T patent/DK3518961T3/da active
- 2017-09-28 LT LTEPPCT/EP2017/074594T patent/LT3518961T/lt unknown
- 2017-09-28 BR BR112019005793A patent/BR112019005793A2/pt unknown
- 2017-09-28 ES ES17781427T patent/ES2943720T3/es active Active
- 2017-09-28 KR KR1020237041945A patent/KR20230170810A/ko active Application Filing
- 2017-09-28 AU AU2017336251A patent/AU2017336251B2/en active Active
- 2017-09-28 SG SG11201901558VA patent/SG11201901558VA/en unknown
-
2019
- 2019-03-25 IL IL265601A patent/IL265601A/en unknown
- 2019-03-25 ZA ZA2019/01813A patent/ZA201901813B/en unknown
-
2020
- 2020-08-10 US US16/989,225 patent/US20200360488A1/en not_active Abandoned
-
2022
- 2022-06-06 JP JP2022091286A patent/JP7434419B2/ja active Active
- 2022-11-08 US US18/053,701 patent/US11857603B2/en active Active
-
2023
- 2023-10-27 US US18/496,727 patent/US20240173385A1/en active Pending